ArticlePediatric research2026
A quest for a histaminergic or orexinergic biomarker for sudden infant death syndrome.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A narrative review of sudden infant death syndrome: pathophysiology, risk factors, and prevention.European journal of pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSudden infant death syndrome (SIDS) occurs predominantly during sleep between 2 and 6 months of age, suggesting impaired maturation of arousal pathways. The neurobiological mechanisms involved remain unclear. We investigated the role of wake-promoting Orexin (Ox) and Histamine (HA) neurons in SIDS.
methodsCerebrospinal fluid (CSF) Ox levels were measured in 61 living controls and 70 Sudden Unexpected Death Infants (SUDI: 38 SIDS, 32 explained deaths (ED)). HA and tele-methylhistamine (t-MeHA) were analyzed in an additional 46 SUDI (34 SIDS, 12 ED) and 42 controls. Immunohistochemistry was performed on hypothalamic tissue from 11 SIDS and 8 ED cases to quantify Ox and HA neuron numbers.
resultsCSF Ox levels did not differ overall between groups but were higher in SUDI infants aged 2-6 months. HA and t-MeHA levels were elevated in SUDI, likely reflecting postmortem release. Ox neuron numbers were increased in rostral hypothalamic region in SIDS compared with EDs, whereas HA neuron numbers were unchanged.
conclusionsSIDS is associated with increased Ox neuronal activity during the peak risk period, possibly reflecting a homeostatic upregulation in response to arousal deficit or repeated stress or hypoxia, while the role of HA system remains to be clarified with more sensitive biomarkers. IMPACT: First study evaluating orexin and histamine systems in SIDS using CSF and postmortem brain tissue. Identifies elevated orexin activity in SIDS infants, particularly in the 2-6 month risk window. No evidence to date for direct histamine involvement; need for more sensitive biomarkers. Suggests orexin system as a potential biomarker for SIDS risk stratification. Highlights the importance of combined neurobiological approaches for prevention.
Identifiers
42332249What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.